Background : Linaclotide is used for treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC) in Japan. However, factors affect ing the efficacy and safety of linaclotide, including occurrence of diarrhea, have not been identified. Object: To determine whether patient baseline characteristics affect the occur rence of diarrhea and spontaneous bowel movement (SBM) frequency, to assess stool form (Bristol stool form scale, BSFS) over time, and to assess changes in diarrhea symp toms with dose reduction, in Japanese patients with IBS-C or CC treated with lina clotide. Method : Retrospective pooled analysis of individual data from two randomized pla cebo-controlled studies with open-label extensions of once-daily linaclotide 0.5 mg (52-56 weeks). Results: Among patients administered linaclotide at least once (randomized and/or extension phase), baseline characteristics did not differ between patients with (n=75) or without (n=425) diarrhea. Diarrhea was well controlled by dose reduction or tempo rary discontinuation ; most patients continued linaclotide with dose reduction. Among patients administered linoclotide during both randomized and extension phases (n=256), there were no differences in adjusted mean of change from baseline to Week 4 in weekly SBM frequency between subgroups (eg, male vs female, body mass index<25 vs ≧25 kg/m2). Over 12 weeks of treatment, the number of patients with diarrhea (BSFS • 6, 7) did not increase and approximately 70% of patients maintained good defecation status. Conclusion : Linaclotide can be used for long-term treatment of constipation in patients with IBS-C or CC, with dose adjustment as needed, regardless of patient char-acteristics.
|Number of pages||13|
|Publication status||Published - 2019|
ASJC Scopus subject areas